The Russian Influenza Institute to Begin Human Trials of COVID-19 Vaccine in mid-August

22 July 2020

GMP News

The Smorodintsev Research Institute of Influenza in St. Petersburg in the middle of August will start clinical trials of a vaccine against the novel coronavirus infection which earlier had successfully passed trials in China. The institute is enlisting the first 100 volunteers.

The recruitment of volunteers for clinical trials of the covid-19 vaccine (phase 3) is ongoing. The vaccine has passed phase 1 and 2 trials in hina. 500 volunteers were inoculated, its safety and effectiveness were proven. The goal of the current study is to demonstrate its effectiveness on the large sampling of volunteers. The scheduled beginning is in the middle of august,” the statement said.

The study participants won’t be hospitalized, the vaccination will be single-staged with the subsequent control check-ups.

Men and women aged 18-60 who hadn’t contracted the coronavirus before may participate in the study. The study does not accept the participants with chronic illnesses, hepatitis, and HIV, as well as with allergic reactions. The study also does not admit pregnant women, drug and alcohol users, people with psychiatric disorders.

Earlier, acting director of the Smorodintsev Research Institute of Influenza Dmitry Lioznov reported that in August the institute will begin clinical trials of three foreign vaccines but did not specify the manufacturers. Additionally, preclinical trials of the vaccine developed at the institute are currently conducted there.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more